Clinical & Preclinical Portfolio
DotBio's first out-licensed asset. A PD1 × VEGFA bispecific antibody built using DotBio's DotBody module, now in Phase II clinical trials. Interim data presented at AACR 2026 demonstrates compelling efficacy in two solid tumor indications.
PD1×VEGF + CTLA4 · N=26 · NCT06954467
PD1×VEGF + chemo · N=32 · NCT06885385
DotBio's lead proprietary asset. A tri-specific antibody with a novel "dead" IL2 tether mechanism that selectively reactivates exhausted CD8+ T-cells in the tumor microenvironment — while avoiding systemic toxicity. Patent filed.
→ TOXICITY
→ SAFETY
| IBI363 | DB007 | |
|---|---|---|
| Efficacy (tumor growth) | Less inhibition | More inhibition |
| Toxicity (mice) | 50% died | Zero deaths |
| T-cell expansion in blood | >400% increase | 30% increase |
| CD8 expansion in tumor | No change | +56% increase |
Next-generation immuno-oncology tri-specific antibody. Lead identified. IND-enabling studies ongoing.
First-in-class intracellular antibody using DotBio's teVLP delivery platform. Targets eIF4E — a key translational regulator upregulated in many tumors — at the eIF4G interaction site, which is undruggable by small molecules. Delivery optimization ongoing.
VEGFA × ANG2 bispecific with best-in-class potential. A VEGF/ANG-2 based trispecific antibody is also under development for broader vascular indications.
IL17-based bispecific antibody targeting rheumatoid arthritis and ankylosing spondylitis. Lead optimization ongoing.
Interested in our pipeline?
DotBio's assets and platform are available for licensing, co-development, and out-licensing partnerships. New modules can be generated against your targets of interest in ~4 months.